In December, 2013, the Life Raft Group launched its “We Are the Cure” campaign to fund GIST research in response to the shrinking pool of available funds. As a rare disease, GIST research is impacted more than other more common cancers like breast and colon. Institutions like the National Cancer Institute are funding just four to five percent of all research proposals which means that a rare cancer like GIST is lost amongst the roughly 200 cancers competing for funding.
The future of cancer treatment relies on patient enrollment in clinical trials. In a recent Chicago Tribune article, a patient story is highlighted to illustrate the important role clinical trials play in cancer treatment, not only in [...]
There are multiple costs associated with cancer treatment. The emotional cost of cancer is obvious: fear and anxiety become constant companions. The economic cost is less apparent initially, as the patient and their support team [...]
The 2014 Zurich Declaration Principles for the transition to “Generic Drugs” for GIST (Gastrointestinal Stromal Tumors) Background and Purpose: GIST (Gastrointestinal Stromal Tumor) is a rare sarcoma, with an annual incidence of about 15 persons [...]
It’s hard to believe that 12 years have passed since the Life Raft Group officially became a non-profit organization. We have accomplished so much during that time, and look forward to accomplishing more, keeping in [...]
Two recent articles highlight the need to focus attention on cancers that have previously been less widely acknowledged by both funding and attention by the general public. The first article from the Genetic Engineering [...]
In preparation for July 13th's GIST Awareness Day we have invited top advocates to share their best strategies on how to campaign for change and raise awareness about GIST.
In a recent article from Biomed Central, the importance of epigenomics and the Human Genome Project and more recent cancer- focused initiatives are discussed. A new paradigm being explored is the idea of C2c (cancer [...]
At the recent American Society of American Oncology Meeting (ASCO), Dr. George Demetri, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, presented results from a collaborative trial that indicates in [...]
A recent article from Cancer Research UK discusses immunotherapy, and the attention its role in the future of cancer treatment may play. In response to the interest in immunotherapy at the 50th Annual Meeting of [...]